Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: A Gynecologic Oncology Group study

Stastical Decision Theory and Bayesian Analysis.

Malay Ghosh, James O. Berger · Journal of the American Statistical Association · 1988 · 2.9K citations

Business, Decision Sciences, Mathematics +14

Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic Disease

Melody Cobleigh, Charles L. Vogel, Debu Tripathy et al. · Journal of Clinical Oncology · 1999 · 2.8K citations

Medicine, Oncology, Pharmacology +17

Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer.

José Baselga, Debu Tripathy, John Mendelsohn et al. · Journal of Clinical Oncology · 1996 · 1.4K citations

Medicine, Oncology, Pharmacology +17

Evaluation of Monoclonal Humanized Anti-HER2 Antibody, Trastuzumab, in Patients With Recurrent or Refractory Ovarian or Primary Peritoneal Carcinoma With Overexpression of HER2: A Phase II Trial of the Gynecologic Oncology Group

Michael A. Bookman, Kathleen M. Darcy, Daniel L. Clarke‐Pearson et al. · Journal of Clinical Oncology · 2003 · 613 citations

Medicine, Gynecology, Oncology +17

Met Receptor Contributes to Trastuzumab Resistance of Her2-Overexpressing Breast Cancer Cells

David L. Shattuck, Jamie K. Miller, Kermit L. Carraway et al. · Cancer Research · 2008 · 470 citations

Medicine, Oncology, Pharmacology +17